Healthcare Global Enterprises Ltd
HCGHealthcare Global Enterprises Ltd's price has outrun its earnings. +10.3% in a year against EPS −69.4% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +10.3% in a year while annual EPS moved −69.4% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (7 weeks in) while the P/E sits at the 89th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit −40.3% year on year, and 840% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Healthcare Global Enterprises Ltd trades at ₹671, in a confirmed uptrend and 7 weeks into that stage. That is +8.3% against its own 200-day average. It sits at 62% of a 52-week range of ₹532 to ₹755. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is in a confirmed uptrend — week 7 of stage 2, confirmed. At ₹671 it trades +8.3% versus its 200-day average and sits at 62% of its 52-week range (₹532–₹755).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +286% while the NIFTY 500 moved +268% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Healthcare Global Enterprises Ltd trades at 349.0× P/E, at the pricey end of its own range (89th percentile). Its long-run median P/E is 157.8×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 349.0× is at the pricey end of its own range (89th percentile), against a long-run median of 157.8× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −69.4% against a +10.3% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 10y, of the +12.8%/yr price move, ~+13.6%/yr came from earnings growth and ~−0.8 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 95% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Healthcare Global Enterprises Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 8.0% — the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +14.7% | +14.6% | +20.3% | +15.9% |
| Profit | −53.1% | +8.5% | — | +27.7% |
| EPS | −69.4% | −22.7% | — | — |
| Share price | +10.3% | +27.6% | +22.0% | +12.8% |
4-Factor Sector Score
35.9/100 — rank 17 of 19 in Hospitals · 65% evidence confidence
Healthcare Global Enterprises Ltd scores 35.9 out of 100 against the 19 companies it is compared with in Hospitals, ranking 17. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 13.1 + 7.4 + 8.5 + 6.9 = 35.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Healthcare Global Enterprises Ltd reported ₹652 Cr of revenue in the Mar 26 quarter, +11.5% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 15.9% a year. The last full year, FY26, came in at ₹2,545 Cr. The last four reported quarters add to ₹2,545 Cr.
FY26 revenue came in at ₹2,545 Cr (+14.7% on the year), capping 10 years at 15.9% compound. The latest quarter (Mar 26) printed ₹652 Cr, +11.5% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +14.6% growth against the decade's 15.9% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +14.5% over the last 4 quarters against +15.4%/yr over the last 8 — stabilising; TTM profit −53.3% vs −25.7%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Healthcare Global Enterprises Ltd's operating margin is 19.2% in the Mar 26 quarter, +1.1 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 9.0% to 18.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 19.2%, +1.1 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0%–18.0%, and FY26's 18.0% is the top of that band — a record year.
Why the margin moved: operating margin went +1.1 pp year on year while gross margin went −0.8 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Healthcare Global Enterprises Ltd earned ₹4.0 Cr of net profit in the Mar 26 quarter, −40.3% year on year. Full-year FY26 profit was ₹23.0 Cr. The 10-year compound rate is 27.7%. That is 0.6% of the quarter's revenue. The same quarter a year earlier earned ₹6.8 Cr. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹4.0 Cr, −40.3% year on year. On the full year, FY26 printed ₹23.0 Cr (−53.1%), and the 10-year compound rate is 27.7%.
🚨 Why profit moved: revenue contributed +11.5% and the margin +1.1 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −74.6% vs revenue +14.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 840% of Healthcare Global Enterprises Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹347 Cr of operating cash against ₹23.0 Cr of profit. After ₹258 Cr of capital spending, ₹89.0 Cr was left as free cash.
FY26: operating cash of ₹347 Cr against reported profit of ₹23.0 Cr, leaving free cash of ₹89.0 Cr after ₹258 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 840% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 840%: the cash cycle stretched 28 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 2.4× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Healthcare Global Enterprises Ltd's cash conversion cycle runs −93 days in FY26, up from −121 days in FY21. Capital spending ran ₹1,539 Cr over the last 3 years. At FY26 sales of ₹2,545 Cr each day of that cycle holds about ₹7.0 Cr, so roughly ₹−648 Cr sits inside the business at any moment.
FY26: debtors at 60 days, inventory at 32 days — roughly 1.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −93 days, looser than FY21's −121.
The full loop: cash goes out to suppliers and production on day 0; stock waits 32 days to sell; customers pay about 60 days after that; and suppliers themselves are paid at 185 days — netting out to the −93-day cycle.
In money terms: at FY26 sales of ₹2,545 Cr, each day of the cycle holds about ₹7.0 Cr — so the −93-day loop keeps roughly ₹−648 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,539 Cr over the last 3 fiscal years against ₹629 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹19.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Healthcare Global Enterprises Ltd earns a ROCE of 8% in FY26. That is up from a trough of −1% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 0.9% net margin on 0.65× asset turns.
FY26 ROCE is 8%, recovered from a FY21 trough of −1% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 0.9% net margin × 0.65× asset turns × 2.95× balance-sheet leverage ≈ 1.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 95% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Healthcare Global Enterprises Ltd carries ₹1,735 Cr of borrowings against ₹1,332 Cr of equity in FY26, a debt-to-equity of 1.30. Operating profit covers the interest bill 3×. Over 5 years borrowings went from ₹977 Cr to ₹1,735 Cr. Capital spending ran ₹1,539 Cr across the last 3 of those years.
FY26: borrowings of ₹1,735 Cr against equity of ₹1,332 Cr — a debt-to-equity of 1.30. Operating profit covers the interest bill 3×. Over 5 years borrowings went from ₹977 Cr to ₹1,735 Cr while capital spending ran ₹1,539 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 95% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 8.3 points of Healthcare Global Enterprises Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 19.2% of the company. Promoters moved −7.1 points over the same window, to 64.2%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +8.3 points over 8 quarters to 19.2%; Promoters: −7.1 points over 8 quarters to 64.2%; Foreign institutions: −1.2 points over 8 quarters to 2.7%.
Why the register moved: domestic institutions drove it (+8.3 points), absorbed on the other side by promoters (−7.1 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Healthcare Global Enterprises Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1KMC Speciality Hospitals (India) Ltd524520 | 82.1/100Sector-leading setup78% evidence | LEADER | 30.8/35 Revenue 32.5% · PAT 100% · OPM change 6 pp 83% evidence | 20.6/25 ROCE 26% · OPM 31% 76% evidence | 11.2/20 P/E 44.5× · PEG — 50% evidence | 19.5/20 RS sector 34% · RS bench 44.3% · 1Y 97.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 20.6 + 11.2 + 19.5 = 82.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Artemis Medicare Services LtdARTEMISMED | 67.9/100Favorable setup96% evidence | LEADER | 24.4/35 Revenue 15.5% · PAT 24.1% · OPM change 3 pp 88% evidence | 12.0/25 ROCE 14.6% · OPM 18% 100% evidence | 14.4/20 P/E 44.6× · PEG 1.09 100% evidence | 17.1/20 RS sector 8.2% · RS bench 17.1% · 1Y 24.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 12 + 14.4 + 17.1 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Sakar Healthcare LtdSAKAR | 67.6/100Favorable setup87% evidence | LEADER | 32.2/35 Revenue 43.9% · PAT 71.4% · OPM change 5 pp 95% evidence | 11.0/25 ROCE 12.7% · OPM 29% 95% evidence | 6.9/20 P/E 54.6× · PEG — 50% evidence | 17.5/20 RS sector 57% · RS bench 68.5% · 1Y 144.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.2 + 11 + 6.9 + 17.5 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Apollo Hospitals Enterprise LtdAPOLLOHOSP | 67.1/100Favorable setup78% evidence | LEADER | 23.6/35 Revenue 15.8% · PAT 33% · OPM change 1 pp 83% evidence | 15.4/25 ROCE 17.9% · OPM 15% 76% evidence | 12.6/20 P/E 65.8× · PEG — 50% evidence | 15.5/20 RS sector 5.2% · RS bench 13.7% · 1Y 19.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 15.4 + 12.6 + 15.5 = 67.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Rainbow Childrens Medicare LtdRAINBOW | 58.0/100Mixed-positive evidence100% evidence | BREAKING OUT | 18.0/35 Revenue 18.3% · PAT 12.4% · OPM change 0 pp 100% evidence | 17.1/25 ROCE 17.4% · OPM 29% 100% evidence | 7.3/20 P/E 54.1× · PEG 2.97 100% evidence | 15.6/20 RS sector 4% · RS bench 12.4% · 1Y -2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 17.1 + 7.3 + 15.6 = 58 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Max Healthcare Institute LtdMAXHEALTH | 57.8/100Mixed-positive evidence90% evidence | TURNING | 25.1/35 Revenue 19.1% · PAT 34% · OPM change 1 pp 88% evidence | 15.8/25 ROCE 14.7% · OPM 28% 100% evidence | 10.8/20 P/E 72.1× · PEG 1.73 100% evidence | 6.1/20 RS sector -7.9% · RS bench 0.1% · 1Y -14.2%2 of 10 weeks ahead 70% evidence |
| Exact sum: 25.1 + 15.8 + 10.8 + 6.1 = 57.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.9% and the one-year return is -14.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Kovai Medical Center & Hospital LtdKOVAI | 54.6/100Mixed-positive evidence96% evidence | FADING | 17.8/35 Revenue 15.8% · PAT 16.2% · OPM change -1 pp 88% evidence | 21.3/25 ROCE 22.6% · OPM 27% 100% evidence | 10.4/20 P/E 26.3× · PEG 1.51 100% evidence | 5.1/20 RS sector -7.4% · RS bench 0.2% · 1Y -3.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 21.3 + 10.4 + 5.1 = 54.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Dr Agarwals Eye Hospital LtdDRAGARWQ | 54.3/100Mixed-positive evidence90% evidence | ASLEEP | 19.6/35 Revenue 18.6% · PAT 27.8% · OPM change -4 pp 88% evidence | 16.8/25 ROCE 17.4% · OPM 28% 100% evidence | 10.6/20 P/E 34.6× · PEG 1.72 100% evidence | 7.3/20 RS sector -4% · RS bench -1% · 1Y 13.4%4 of 7 weeks ahead 70% evidence |
| Exact sum: 19.6 + 16.8 + 10.6 + 7.3 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Global Health LtdMEDANTA | 54.1/100Mixed-positive evidence100% evidence | LEADER | 12.3/35 Revenue 21.3% · PAT 3.4% · OPM change -2 pp 100% evidence | 13.9/25 ROCE 17.1% · OPM 22% 100% evidence | 11.3/20 P/E 66× · PEG 1.11 100% evidence | 16.6/20 RS sector 4.5% · RS bench 13% · 1Y 6.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 13.9 + 11.3 + 16.6 = 54.1 · Decision use: Price leads the evidence: RS versus the benchmark is 13%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Indraprastha Medical Corporation LtdINDRAMEDCO | 52.2/100Mixed-positive evidence90% evidence | ASLEEP | 12.4/35 Revenue 9.3% · PAT 13.7% · OPM change -1 pp 88% evidence | 18.6/25 ROCE 35.8% · OPM 17% 100% evidence | 17.2/20 P/E 18.3× · PEG 0.92 100% evidence | 4.0/20 RS sector -8.4% · RS bench -17.3% · 1Y -20.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 18.6 + 17.2 + 4 = 52.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11Fortis Healthcare LtdFORTIS | 50.2/100Mixed-positive evidence78% evidence | FADING | 23.6/35 Revenue 17.3% · PAT 31.5% · OPM change 1 pp 83% evidence | 12.8/25 ROCE 13.4% · OPM 23% 76% evidence | 9.0/20 P/E 67.5× · PEG — 50% evidence | 4.8/20 RS sector -7.3% · RS bench 0.2% · 1Y 11.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 12.8 + 9 + 4.8 = 50.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.3% and the one-year return is 11.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Yatharth Hospital & Trauma Care Services LtdYATHARTH | 48.2/100Mixed-negative evidence78% evidence | FADING | 19.5/35 Revenue 36.1% · PAT 31.5% · OPM change -2 pp 83% evidence | 11.7/25 ROCE 12.4% · OPM 23% 76% evidence | 8.8/20 P/E 45× · PEG — 50% evidence | 8.2/20 RS sector 0.2% · RS bench 8.1% · 1Y 30.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 11.7 + 8.8 + 8.2 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13GPT Healthcare LtdGPTHEALTH | 47.9/100Mixed-negative evidence70% evidence | TURNING | 10.3/35 Revenue 16% · PAT -14% · OPM change -2 pp 83% evidence | 18.5/25 ROCE 19.9% · OPM 18% 95% evidence | 11.2/20 P/E 32.5× · PEG — 15% evidence | 7.9/20 RS sector -15.8% · RS bench 17.9% · 1Y 5.9%10 of 10 weeks ahead 70% evidence |
| Exact sum: 10.3 + 18.5 + 11.2 + 7.9 = 47.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Aster DM Quality Care LtdASTERDM | 39.4/100Mixed-negative evidence96% evidence | LEADER | 12.6/35 Revenue 12.2% · PAT -80% · OPM change 1 pp 88% evidence | 9.8/25 ROCE 11.4% · OPM 19% 100% evidence | 1.5/20 P/E 176× · PEG 3.07 100% evidence | 15.5/20 RS sector 10.8% · RS bench 19.6% · 1Y 41.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 9.8 + 1.5 + 15.5 = 39.4 · Decision use: Price leads the evidence: RS versus the benchmark is 19.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Krishna Institute of Medical Sciences LtdKIMS | 39.4/100Mixed-negative evidence78% evidence | LEADER | 10.4/35 Revenue 28.7% · PAT -41.5% · OPM change -6 pp 83% evidence | 9.2/25 ROCE 9.3% · OPM 19% 76% evidence | 5.5/20 P/E 136× · PEG — 50% evidence | 14.3/20 RS sector 3.7% · RS bench 12% · 1Y 5.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 10.4 + 9.2 + 5.5 + 14.3 = 39.4 · Decision use: Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Narayana Hrudayalaya LtdNH | 39.3/100Mixed-negative evidence87% evidence | TURNING | 12.6/35 Revenue 59.6% · PAT 3.8% · OPM change -5 pp 100% evidence | 11.6/25 ROCE 15.5% · OPM 17% 100% evidence | 6.1/20 P/E 48.1× · PEG 3 65% evidence | 9.0/20 RS sector -4.3% · RS bench 9.2% · 1Y 1.9%5 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 11.6 + 6.1 + 9 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Healthcare Global Enterprises Ltdthis pageHCG | 35.9/100Mixed-negative evidence65% evidence | TURNING | 13.1/35 Revenue 14.5% · PAT -53.4% · OPM change 1.1 pp 83% evidence | 7.4/25 ROCE 8.3% · OPM 19.2% 76% evidence | 8.5/20 P/E 349× · PEG — 15% evidence | 6.9/20 RS sector -8.1% · RS bench 3.4% · 1Y 18.5%8 of 10 weeks ahead 70% evidence |
| Exact sum: 13.1 + 7.4 + 8.5 + 6.9 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Shalby LtdSHALBY | 30.7/100Adverse evidence69% evidence | ASLEEP | 15.6/35 Revenue 4.8% · PAT 100% · OPM change 2 pp 62% evidence | 2.5/25 ROCE 6.5% · OPM 10% 95% evidence | 9.1/20 P/E 46.6× · PEG — 50% evidence | 3.5/20 RS sector -28.4% · RS bench -14.9% · 1Y -22.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 15.6 + 2.5 + 9.1 + 3.5 = 30.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Jupiter Life Line Hospitals LtdJLHL | 29.8/100Adverse evidence100% evidence | BASING | 8.4/35 Revenue 14.7% · PAT -3.1% · OPM change -3 pp 100% evidence | 10.5/25 ROCE 14.8% · OPM 19% 100% evidence | 6.4/20 P/E 56.9× · PEG 3.44 100% evidence | 4.5/20 RS sector -74.8% · RS bench 17.9% · 1Y -77.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 8.4 + 10.5 + 6.4 + 4.5 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Healthcare Global Enterprises Ltd's share price today?
Healthcare Global Enterprises Ltd trades at ₹671, +10.3% over the past year. The company is valued at ₹10,021 Cr. The stock sits at 62% of its 52-week range of ₹532–₹755, +8.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 7 weeks in. — as of 31 July 2026.
What were Healthcare Global Enterprises Ltd's latest quarterly results?
Healthcare Global Enterprises Ltd reported revenue of ₹652 Cr and net profit of ₹4.0 Cr for the Mar 26 quarter. Revenue rose 11.5% and profit fell 40.3% year on year. Earnings per share were ₹0.15. The operating margin was 19.2%, 1.1 pp higher than a year earlier. — as of 31 July 2026.
What is Healthcare Global Enterprises Ltd's revenue?
Healthcare Global Enterprises Ltd reported revenue of ₹652 Cr in the Mar 26 quarter, +11.5% year on year. For the full FY26 fiscal year, revenue was ₹2,545 Cr (+14.7%). Over the last 10 years revenue compounded at 15.9% a year. — as of 31 July 2026.
What is Healthcare Global Enterprises Ltd's profit?
Healthcare Global Enterprises Ltd earned ₹4.0 Cr of net profit in the Mar 26 quarter, −40.3% year on year. Full-year FY26 profit was ₹23.0 Cr. The operating margin ran 19.2% in the latest quarter. — as of 31 July 2026.
What is Healthcare Global Enterprises Ltd's market cap?
Healthcare Global Enterprises Ltd's market capitalisation is ₹10,021 Cr at a share price of ₹671. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Healthcare Global Enterprises Ltd's P/E ratio?
Healthcare Global Enterprises Ltd trades at a P/E of 349.0×, at the 89th percentile of its own 10-year range, against a long-run median of 157.8×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Healthcare Global Enterprises Ltd pay a dividend?
No — Healthcare Global Enterprises Ltd has recorded a dividend payout of 0% of profit in each of its last 13 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is Healthcare Global Enterprises Ltd overvalued?
On its own history, Healthcare Global Enterprises Ltd looks expensive against its own history: its P/E of 349.0× sits at the 89th percentile of its 10-year range (long-run median 157.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.
Is Healthcare Global Enterprises Ltd growing?
Yes — Healthcare Global Enterprises Ltd is growing: latest-quarter revenue +11.5% year on year, profit −40.3%, and the margin +1.1 pp at 19.2%. The 10-year compound rates are 15.9% (revenue) and 27.7% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Healthcare Global Enterprises Ltd performing?
Healthcare Global Enterprises Ltd is in a confirmed uptrend, 7 weeks in. Its latest quarter's revenue rose 11.5% and profit fell 40.3% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Healthcare Global Enterprises Ltd in?
Mixed — no clean majority across the growth curves, ROCE holding at 8.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +11.5% latest, profit growth −40.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Healthcare Global Enterprises Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 7 of stage 2), trading +8.3% versus its 200-day average and at 62% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Healthcare Global Enterprises Ltd beating the market?
On recent form, yes — Healthcare Global Enterprises Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +286% against the NIFTY 500's +268% — ahead of the index over the full window. — as of 31 July 2026.
Will Healthcare Global Enterprises Ltd's share price go up?
This page publishes no price forecast for Healthcare Global Enterprises Ltd. What it measures instead: the share price is ₹671, the price is in a confirmed uptrend 7 weeks in. Its P/E of 349.0× sits at the 89th percentile of its own 10-year range. — as of 31 July 2026.
Who owns Healthcare Global Enterprises Ltd?
Promoters hold 64.2% of Healthcare Global Enterprises Ltd, foreign institutions 2.7%, domestic institutions 19.2% and the public 13.9% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 8.3 points over 8 quarters. — as of 31 July 2026.
Does Healthcare Global Enterprises Ltd have too much debt?
It carries real leverage — Healthcare Global Enterprises Ltd's debt-to-equity is 1.30, and operating profit covers the interest bill 3×. FY26 borrowings were ₹1,735 Cr against equity of ₹1,332 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Healthcare Global Enterprises Ltd's capex?
Healthcare Global Enterprises Ltd spent ₹1,539 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹258 Cr, with ₹19.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Healthcare Global Enterprises Ltd's cash flow?
Healthcare Global Enterprises Ltd generated ₹347 Cr of operating cash flow in FY26 and ₹89.0 Cr of free cash flow after ₹258 Cr of capital spending. Reported profit that year was ₹23.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Healthcare Global Enterprises Ltd's profit real cash?
Yes — over the last 3 fiscal years, 840% of Healthcare Global Enterprises Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹347 Cr against reported profit of ₹23.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Healthcare Global Enterprises Ltd in its business cycle?
Healthcare Global Enterprises Ltd's FY26 operating margin was 18.0%, against a 13-year band of 9.0%–18.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 19.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Healthcare Global Enterprises Ltd story?
The sharpest disagreement: the price moved +10.3% in a year while annual EPS moved −69.4% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Healthcare Global Enterprises Ltd a stock worth studying right now?
This is not investment advice. The machine read: Healthcare Global Enterprises Ltd's price has outrun its earnings. +10.3% in a year against EPS −69.4% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.